Member Info for Spikeyj

next sell order set in 1700s.

some of my wpct re-bought in the 80s in exchange for more gsk. still think the story & idea here is a good one, but imv not enough evidence so far of sufficiently accurate stockpicks, plus couple of due diligence slips. hopefully he will bring a bit more zing here when one or two stakes get ipo'd / sold off, e.g nanopore i think could be a very good one. gla.

Nov 16 (Reuters) - British insurer Prudential Plc reported a 19 percent rise in new business profit for the first nine months of the year, driven mainly by strong performance at its Asian business, and said it planned to boost its dividend. The life insurer has been focusing its growth efforts on Asia's expanding middle class, with its Asian business contributing around a third of Prudential's operating profit. Prudential, which serves about 24 million insurance customers and has 562 billion pounds of assets under management, said new business profit rose to 1.97 billion pounds ($2.46 billion) from 1.66 billion pounds a year earlier. Group Annual Premium Equivalent (APE) sales, which include regular premium sales plus one-tenth of single premium insurance sales, rose 16 percent to 4.55 billion pounds, the insurer said. The company said it would aim to raise its ordinary dividend by 5 percent every year. Prudential said new business profit from Asia increased 34 percent on an actual exchange rate basis to 1.31 billion pounds in the period, while APE sales jumped 25 percent. The firm saw a 41 percent rise in new business profit from retail sales in its British life business to 179 million pounds, helped by the popularity of its with-profits product range, Prudential said in a statement. New business profit at the U.S. business fell 13 percent to 485 million pounds, however, after the Department of Labor tightened rules about the sale of variable annuities, which offer a variable rate of income often above a guaranteed minimum level.

share puppets hedging their bets re DWHT "Previously writing on Dewhurst (DWHT) on a February AGM update, I noted further negative macro read-across. The company has now updated including “whilst seasonal effects mean the company's second half is traditionally stronger than the first half, the effect in FY16 has been greater than usual”. This sees “the board currently expect group revenues for FY16 to exceed £47.0 million with a positive impact on profits compared with current market expectations”. This follows half year results to 31st March 2016 having shown earnings per share down from a prior year 18.6p to 13.1p on revenue down from £22.8 million to £21.3 million. The prior year’s half-year performance evolved into full-year earnings per share of 52p on revenue of £45.9 million. It is noted “a significant proportion of Dewhurst's sales and earnings are generated in foreign currencies and the depreciation of pound sterling during FY16 has continued to benefit Dewhurst's reported sales and profits” - and there looks to be good improvement from the February update-stated “lower short term demand” and “margin pressures”. The shares have recovered from sliding from more than 650p on 1st February to 550p, to presently 675p. The current macroeconomic climate sees me particularly wary of self-admitted “lead time from order to invoicing of our products is generally very short, which also means the visibility of changes in demand is equally short”. However, with a view to the further detail of full-year results expected “by mid-December”, this looks one for watchlists. - See more at: http://www.*************.com/views/25261/dewhurst-performance-from-materially-below-to-positive-compared-with-current-market-expectations#sthash.DAJqJEfB.dpuf"

RNS they are getting on with growth.

? you could use one of the 'general chat' boards on lse?

well, at least you got a couple of quid head start on my last add. : )

perhaps there's also something about the comforting illusion (?) that trump may be more friendly to britain than clinton would have been, so that in turn might make brexit more productive/less painful, with +ve implication for £, etc, blah blah. .. lots of big moves recently on limited evidence.

perhaps also about changing expectations for some in market re exchange rates? GSK is a big $$ earner. election of trump seems to indicate US may resort to significantly higher borrowing for his expansionary plans. related to the above, also about asset switching; expansionary policy from trump may lead to better profits from us financial sector, so some asset managers etc. moving money out of pharmas into financial sector shares instead?

worn off. added.

maybe dwha should diversify into big red buttons, if there is a chance these will be used more?

and another slice off. cheers donaldo!

took out a slice in 1540s, part for cash, part for voda. still plenty long here as a longer term hold. strange times that we live in, eh.

thank you Donald.

back from 'safe' pharmas into 'exciting' financials today. ... world trying to make sense of donald trump. (good luck with that, world!)

lol, i shoulda timed that better.

perkier, thankfully.

added a smidge

took a little slice off.

"(ShareCast News) - Astrazeneca is expected to report a drop in third quarter sales on Thursday after failing to prevent generic drug makers from bringing cheaper rivals of its best-selling medicine Crestor. Analysts expect generic versions of cholesterol fighting drug Crestor will have sent revenue down 1% to $5.87bn in the three months to September, down from $5.95bn a year earlier. The group is expected to reveal net income of $731m, down 5% from the $770m the previous year. Deutsche Bank expects product sales to decline by 10% at a constant exchange rate and core earnings per share to drop about 4%, due to the erosion of Crestor and divestments. Generic versions of heartburn medicine Nexium are also expected to have provided a drag. Astrazeneca is looking to boost sales growth with new drugs, including blood-thinner Brilinta and Tagrisso for lung cancer. Deutsche Bank said Tagrisso should benefit from continued US growth and its recent launch in Japan. The bank also sees Brilinta continuing to show solid growth with US prescriptions increasing 40% year-on-year. Deutsche Bank added that risks to Astrazeneca include failure to deliver cost savings, lower platform sales, pipeline failure and a fall in sales of pipeline drugs. Meanwhile, investors will be looking for an update following's last month's setback on its experimental cancer medicine duralumab. The company suspended recruitment for two large clinical trials on durvalumab while it investigates some instances of bleeding among participants."